Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed cases of Graham–Little-Piccardi–Lassueur syndrome and found that topical treatments were generally ineffective, while systemic therapies like prednisone, hydroxychloroquine, and isotretinoin led to partial hair regrowth and disease stabilization, highlighting the importance of early diagnosis and systemic therapy to improve outcomes.

In this case report, a 26-year-old man with alopecia universalis, resistant to multiple standard treatments, achieved complete and sustained hair regrowth with ruxolitinib, highlighting its potential as a promising option for patients with refractory AU.

In this study, specific genetic polymorphisms in the KRT71 gene were associated with hairless and curly phenotypes in Sphynx and Devon Rex cats.

This review discusses various applications of low level laser therapy and argues for a holistic evaluation of patients but reports no new clinical findings.

In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study found that simultaneously inhibiting both KLK5 and KLK7 proteases completely rescued skin barrier defects in a mouse model of Netherton syndrome, suggesting both should be therapeutic targets.

This study reports that a clinical prognostic model based on immune-related genes improved survival prediction for patients with clear cell renal cell carcinoma, also identifying potential drugs targeting the gene DOCK8.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

This study identified expression patterns of long non-coding RNAs during the hair follicle cycle in yak, revealing potential functions and sequence conservation with cashmere goats.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

This article discusses the human KRT72 wild-type allele's role in hair formation and reports no new research findings.

This letter to the editor discusses lichenoid keratosis as a potential cause of localized alopecia areata but reports no new clinical findings.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This study suggests that the EULAR/ACR classification criteria for SLE may help predict organ damage, particularly in renal, cardiovascular, dermatological, and gonadal domains.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

The LTF gene may help predict and manage nonspecific orbital inflammation.

In this study, researchers analyzed skin samples from Dorper sheep to identify 395 differentially expressed long non-coding RNAs (lncRNAs) linked to hair follicle growth phases, suggesting these lncRNAs may play a role in the regulation of hair shedding through pathways like estrogen and PI3K-Akt signaling.

This review discusses the role of LPA(3) in embryo implantation and its genetic connection with prostaglandin signaling, but reports no new clinical results.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

This study found that their newly developed ADRL framework significantly improved the accuracy of scalp tissue layer segmentation in HR-MR images compared to existing methods.

In this study, significant differences in the expression of type I IRS keratin genes were observed in the groins of three sheep breeds during wool growth, related to hair follicle density.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

This study found that overexpressing Rps14 in supporting cells promoted hair cell regeneration in the organ of Corti by facilitating cell proliferation and differentiation.

This study observed that lupus erythematosus-specific skin lesions were more common than nonspecific ones and can serve as diagnostic clues, while nonspecific lesions were more often linked to systemic disease.